Traditional Chinese Medicine Intervenes in Atherosclerosis by Regulating TLR/NLRP3 Pathway via TRPV1/TRPA1
10.13422/j.cnki.syfjx.20231239
- VernacularTitle:基于TRPV1/TRPA1调控TLR/NLRP3通路探讨中医药干预动脉粥样硬化研究进展
- Author:
Peizhang ZHAO
1
;
Zhen YANG
2
;
Xiangyun CHEN
2
;
Xuguang TAO
3
;
Yujie QI
3
;
Zhanzhan HE
3
;
Ce CHU
3
;
Yulu YUAN
3
;
Wei DING
2
;
Yuxin ZHANG
3
;
Yongqi XU
3
;
Hongxia ZHAO
3
;
Wenlai WANG
3
Author Information
1. West China Clinical Medical College， Sichuan University， Chengdu 610041， China
2. Beijing University of Chinese Medicine， Beijing 100029， China
3. Institute of Basic Theory for Traditional Chinese Medicine， China Academy of Chinese Medical Sciences， Beijing 100700， China
- Publication Type:Journal Article
- Keywords:
atherosclerosis;
transient receptor potential vanilloid subtype 1;
Toll-like receptor;
NOD-like receptor protein 3 （NLRP3） inflammasome;
research progress
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(20):247-256
- CountryChina
- Language:Chinese
-
Abstract:
Atherosclerosis is a chronic inflammatory disease caused by lipid accumulation and vascular endothelial dysfunction. The Toll-like receptor （TLR）/nuclear transcription factor-κB （NF-κB） pathway and the NOD-like receptor protein 3 （NLRP3） inflammasome pathway play a proinflammatory role， while the transient receptor potential vanilloid subtype 1 （TRPV1） and transient receptor potential ankyrin 1 （TRPA1） play a protective role in the occurrence of atherosclerosis. We reviewed the relevant studies published in the last 10 years. The results showed that activation of TRPV1/TRPA1 could activate endothelial-type nitric oxide synthase （eNOS） and inhibit the generation of reactive oxygen species （ROS） and cholesterol crystal （CC） to modulate the TLR/NF-κB and NLRP3 inflammasome pathways， thereby inhibiting TLR/NLRP3-mediated inflammatory response. A variety of compound prescriptions and active components of Chinese medicinal materials can activate TRPV1/TRPA1 or its downstream pathway to regulate the TLR/NLRP3 pathway in atherosclerosis. This paper introduces the mechanisms of compound prescriptions and active components of Chinese medicinal materials in regulating the TLR/NLRP3 pathway via TRPV1/TRPA1 in atherosclerosis. This review provides new ideas for the research on the interactions between Chinese medicines in the treatment of atherosclerosis and provides a new strategy for the clinical treatment of atherosclerosis with traditional Chinese medicine.
